How Can We Help?
Skip to content
Wire frame hand with test tube


New Cysteine Trapping Study Now Available for More Efficient & Effective Early Phase Drug-Induced Liver Injury (DILI) Evaluation

  • December 29, 2021

DILI is a leading cause of adverse events in clinical trials, so SEKISUI offers a variety of in vitro studies...

SEKISUI Named to the CDP A List in Both Climate Change and Water Security

  • December 21, 2021

Our parent company, SEKISUI CHEMICAL CO., LTD. has been awarded a place on the Climate Change A List and Water...

SEKSIUI XenoTech expands access to Microsomal Protein Binding service for DMPK profile development and DDI assessment of new drugs

  • December 6, 2021

To help customers more easily investigate how much of their drug will be available to bestow its intended therapeutic effect, SEKISUI XenoTech is now offering…

SEKSIUI XenoTech expands access to Red Blood Cell Partitioning service for improved pharmacokinetics assessments

  • May 5, 2021

To help customers better investigate their compounds’ clearance in preclinical drug development, SEKISUI XenoTech has expanded in vitro service capabilities...

Introducing New CryostaX Individual Donor Human Hepatocytes

  • March 1, 2021

Using single donor hepatocytes just got a whole lot easier. We’ve just released new Single Donor CryostaX®. If you’ve used...

SEKISUI again awarded as one of the most sustainable companies in the world!

  • January 27, 2021

The Canadian organization “Corporate Knights” annually ranks the 100 most sustainable companies in the world in its “Global 100” index....

ADME & DDI Contract Research Organization Announces New Website Launch

  • September 18, 2020

KANSAS CITY, Kansas– SEKISUI XenoTech, a specialty contract research organization (CRO) providing superior nonclinical studies and assay products to pharmaceutical...

SEKISUI XenoTech Receives New US Patent for a Method to Evaluate Xenobiotics as Immune-Modulators of Drug Transport and Metabolism in Hepatocytes

  • May 12, 2020

Kansas City, KS– SEKISUI XenoTech has been awarded US patent # 10,648,968 “In vitro test system to evaluate xenobiotics as...

SEKISUI XenoTech Expands Access to Top-Tier DDI Expertise & Consultancy

  • May 4, 2020

Kansas City, KS – SEKISUI XenoTech is expanding opportunities for clients to work with top-tier consultants to evaluate drug-drug interaction...

New Head of KC-Based Drug Development CRO Poised for Further Growth and Expansion

  • January 28, 2020

SEKISUI XenoTech announces the promotion of Dr. Darren Warren to President and Chief Executive Officer...